Inventor
MATTHEW RANDOLPH LEE
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds41%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
A61KPreparations for medical, dental or toiletry purposes24%
H05KPrinted circuits6%
PatentTitleYear
12,371,435Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors202511,932,633KRas G12C inhibitors202411,912,719Substituted isoquinolines as rock kinase inhibitors202411,485,738Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors202211,267,812KRAS G12C inhibitors202211,248,004Substituted isoquinolines as rock kinase inhibitors202211,220,509Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to MIRATI THERAPEUTICS INC (5)· patent assignee history
2022–2024Patents assigned to ARRAY BIOPHARMA INC (2)· patent assignee history
2022–2024Patents assigned to Cervello Therapeutics LLC (2)· patent assignee history
2022–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MIRATI THERAPEUTICS INC | 5 | 2022–2025 |
| ARRAY BIOPHARMA INC | 2 | 2022–2024 |
| Cervello Therapeutics LLC | 2 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2025 |